9999999997-11-015754.txt : 20110922 9999999997-11-015754.hdr.sgml : 20110922 20110922122608 ACCESSION NUMBER: 9999999997-11-015754 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20110922 DATE AS OF CHANGE: 20110922 20110922 20110922 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ELITE PHARMACEUTICALS INC /DE/ CENTRAL INDEX KEY: 0001053369 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223542636 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 001-15697 FILM NUMBER: 111102674 BUSINESS ADDRESS: STREET 1: 165 LUDLOW AVENUE CITY: NORTHVALE STATE: NJ ZIP: 07647 BUSINESS PHONE: 2017502646 MAIL ADDRESS: STREET 1: 165 LUDLOW AVENUE CITY: NORTHVALE STATE: NJ ZIP: 07647 CT ORDER 1 filename1.pdf begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``+V%PRH@!&(61@X&I#% MF*&8@:&1@9N!_9D93*5(%%1'&U@7@_(9")^1'2#``-E`!3@-"F5N9'-T7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@ M,"!O8FH-/#PO0V]N=&5N=',@,30@,"!2+T-R;W!";WA;,"`P(#8Q,B`W.3)= M+TUE9&EA0F]X6S`@,"`V,3(@-SDR72]087)E;G0@."`P(%(O4F5S;W5R8V5S M(#$V(#`@4B]2;W1A=&4@,"]4>7!E+U!A9V4^/@UE;F1O8FH-,3,@,"!O8FH- M/#PO1FEL=&5R+T9L871E1&5C;V1E+T9I?'R(?I8%(7 MZUGF\-0VQJZV[+YN2EVXT).7I%#1%ZN+?#6N-H4!SE)KRD?\S[&OC[@DNC:LV/YZG>=/:ZZUN()!G6:C1U*2O MNF,(H5CZ_,.2H*QY-D[941X^O;;;=B$C#C0B[M?^("P(`O`<8OQM_ND-)67W MI1G'"F)TG5*)FT$R="R*#\/0\S!.''\KBF*'^G?X<3V,4UYBAO@&[[X^(E7B M*\$UP4HH=F![)FD(/+)\KPGCUR;DZC(3_M-_X1O^2^3[['>I\R0_X=N]]WG/-4Q8OO=N=M.@YQ#&?NK\@N>YCSN]^C$W\+,``O+HA_#0IE;F1S=')E86T-96YD;V)J#3$T(#`@ M;V)J#3P\+T9I;'1EX?<%XW@B!##,;L@)'6FFR6AF[";TR-N/+ M9O+W6WT+A)`,"+ML=Y^J.G6JS*>;-8/'=G"5#CZEJ0\,TNV`^>#A%T^)![$W MIN,0TOW`@T?\I;D\/`T(..F_`S8&EU$607IM[J2_&\,-:)(IZ MMH(;QQUC^JO),ETL;S#"Y5R%QGP:AE@3N]LWNR-?[UYHL7 MAC'<.(K.DO(M^=)C^F4&EC(D:V8H@LDTA;LYL"20%?!):`"Q&F'T?J;HSS]S M%UH.I24=STK1`'BXMP1^W-1_^;''0K6>QB=:)/]<^JAUV`6A[@))G8D@/,K;>T/Z<>1=SM&DU_:;O2/+++J.%Y!5D!T.):[H1%U!7Q4HKY43TX#T#AXP,3_< MN#XT_$?/VTY4CYHA;#792T>-FACRNMHBG0$1!:\ZD3D1^BJA:[@VN[V3X`F? M@5Y7RX:(20.BLC<8'AN]3H^PVV6,?":E][DTJP;)$2U%=%K9]!O;4,:]@7AG&0G(<^R;LA M1'!/UW1*(8K\![)YIS6S:%N-.A< MR,`Y[##W@G<&[,CY&=R;R[T2GB)YU,3LA^4H( M=Z17`@?>B+IHH3WP7&JJ^&Q#4[CO#E'3$\H=#KLP,>\B`-NDX*CF8!Z-/;3# M4/5P4_>/._-(=9]9-30&-N)(1Z#'96C$=1&7_1+7#]X#_F56IR3:3I\;%J?8 M9XI&T4J-#F636T$;T5I=)^R"=)A6X25A#U&43=MGE1*H_H>@4#Z<904JXS%3 MKX2^V]6-Z)X_?S#.WAKJA87K%-/X64O6&'9\K>FK]$G@*93]EDD#_]X10^^5 M//G'VXTR[$F!1*255XD<(W:JO7%WT'#.NYM'=,"%,=@@FXURY-W"^> M^>GNR%>[32R*)TW(+!W\+\``+!2VO0T*96YDG)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835`@0V]R92`T+C(N,2UC,#0S(#4R M+C,W,C&UL;G,Z&UL;G,Z<&1F/2)H='1P.B\O;G,N861O M8F4N8V]M+W!D9B\Q+C,O(CX*("`@("`@("`@/'!D9CI0&UP.D-R M96%T941A=&4^,C`Q,2TP.2TR,E0Q,CHR,SHP-"TP-#HP,#PO>&UP.D-R96%T M941A=&4^"B`@("`@(#PO&UP34TZ26YS=&%N8V5)1#YU=6ED.F)F,#%B M8C=D+31B,V(M-#%E-"TX-#8Q+6,Y-C@Y9#0S.3$Y,3PO>&UP34TZ26YS=&%N M8V5)1#X*("`@("`@/"]R9&8Z1&5S8W)I<'1I;VX^"B`@(#POJ'5!:D MZ@